AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Home
/
insight
/
details

Unlocking the Potential of Oligonucleotide Therapies in Modern Medicine

NextEdge Admin

08 Jun 2024

3 min 15 sec

In the ever-evolving landscape of medical science, oligonucleotide therapies have emerged as an innovative approach with far-reaching implications. These therapies, utilizing short DNA or RNA molecules, hold immense promise in the treatment of various diseases, including cancer, genetic disorders, and infectious diseases.

Oligonucleotide therapies represent a paradigm shift in precision medicine, offering targeted interventions at the molecular level. By employing the power of nucleic acids, researchers can selectively modulate gene expression, protein activity, and cellular pathways implicated in disease pathogenesis. This level of specificity minimizes off-target effects and holds the potential for personalized treatment strategies tailored to individual patients.

One of the most prominent applications of oligonucleotide therapies lies in cancer treatment. Here, these therapies are employed to silence oncogenes, inhibit tumor growth, and enhance the body's immune response against cancer cells. For instance, small interfering RNA (siRNA) molecules can be designed to target and suppress the expression of key genes driving tumor progression. Similarly, antisense oligonucleotides offer a means to modulate gene expression and disrupt cancer-promoting pathways.

Beyond cancer, oligonucleotide therapies hold promise in the treatment of genetic disorders. By targeting specific genes or regulating splicing events, these therapies offer hope for patients with conditions such as spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD). Nusinersen (Spinraza), an antisense oligonucleotide approved for SMA, exemplifies the transformative impact of oligonucleotide therapies in addressing genetic diseases. Some other notable example are the approval of Patisiran (Onpattro) and Inotersen (Tegsedi) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR). These RNA interference (RNAi) therapies represent a landmark achievement in oligonucleotide-based medicine, showcasing the efficacy of gene silencing in mitigating disease pathology.

Moreover, oligonucleotide-based approaches are being explored for infectious diseases. For instance, they can be utilized to inhibit viral replication, interfere with viral gene expression, and enhance the host immune response against pathogens. While no oligonucleotide therapies for infectious diseases have been approved on a large scale, ongoing research holds promise for future breakthroughs in this area.